Oncology Central

KEYNOTE-042: pembrolizumab may be more effective than chemo for advanced NSCLC

Results of the KEYNOTE-042 study – the largest clinical trial of the immunotherapy drug pembrolizumab as a standalone therapy, have demonstrated pembrolizumab to be more effective in most patients with the most common form of lung cancer, in comparison to the current standard-of-care, namely, chemotherapy.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.